L
Lars Pape
Researcher at Hannover Medical School
Publications - 187
Citations - 4273
Lars Pape is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 33, co-authored 170 publications receiving 3392 citations.
Papers
More filters
Journal ArticleDOI
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
Oliver Gross,Christoph Licht,Hans J. Anders,Bernd Hoppe,Bodo B. Beck,Burkhard Tönshoff,Britta Höcker,Simone Wygoda,Jochen H. H. Ehrich,Lars Pape,Martin Konrad,Wolfgang Rascher,Jörg Dötsch,Dirk E. Müller-Wiefel,Peter F. Hoyer,Bertrand Knebelmann,Yves Pirson,Jean-Pierre Grünfeld,Patrick Niaudet,Pierre Cochat,Laurence Heidet,Said Lebbah,Roser Torra,Tim Friede,Katharina Lange,Gerhard A. Müller,Manfred Weber +26 more
TL;DR: Alport syndrome is treatable with angiotensin-converting enzyme inhibition to delay renal failure and therapy improves life expectancy in a time-dependent manner and supports the need for early diagnosis and early nephroprotective therapy in oligosymptomatic patients.
Journal ArticleDOI
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Larry A. Greenbaum,Marc Fila,Gianluigi Ardissino,Samhar I. Al-Akash,Jonathan R. Evans,Paul Henning,Kenneth Lieberman,Silvio Maringhini,Lars Pape,Lesley Rees,Nicole C. A. J. van de Kar,Johan Vande Walle,Masayo Ogawa,Camille L. Bedrosian,Christoph Licht +14 more
TL;DR: The findings establish the efficacy and safety of eculizumab for pediatric patients with aHUS and are consistent with proposed immediate eculIZumab initiation following diagnosis in children.
Journal ArticleDOI
Mutations in Multiple PKD Genes May Explain Early and Severe Polycystic Kidney Disease
Carsten Bergmann,Jennifer von Bothmer,Nadina Ortiz Brüchle,Andreas Venghaus,Valeska Frank,Henry Fehrenbach,Tobias Hampel,Lars Pape,Annegret Buske,Jon J. Jonsson,N. Sarioglu,Antónia Santos,Jose Ferreira,Jan U. Becker,Reinhold Cremer,Julia Hoefele,Marcus R. Benz,Lutz T. Weber,Reinhard Buettner,Klaus Zerres +19 more
TL;DR: In this article, severely affected patients with PKD who carry, in addition to their expected familial germ-line defect, additional mutations in PKD genes, including HNF-1β, which likely aggravate the phenotype.
Journal ArticleDOI
Mycophenolate Mofetil versus Cyclosporin A in Children with Frequently Relapsing Nephrotic Syndrome
TL;DR: It is indicated that MMF is inferior to CsA in preventing relapses in pediatric patients with FR-SSNS, but may be a less nephrotoxic treatment option.
Journal ArticleDOI
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome
Oliver Gross,Burkhard Tönshoff,Lutz T. Weber,Lars Pape,Kay Latta,Henry Fehrenbach,Baerbel Lange-Sperandio,Hildegard Zappel,Peter F. Hoyer,Hagen Staude,Sabine U. König,Ulrike John,Jutta Gellermann,Bernd Hoppe,Matthias Galiano,Britta Hoecker,Rasmus Ehren,Christian Lerch,Clifford E. Kashtan,Markus Harden,Jan Boeckhaus,Tim Friede,Michael Koziolek,Carsten Paul Bramlage,Frauke Weber,Tanja Albrecht-Nock,Joseph Sonntag,Jenny Frese,Matthias Kettwig,Reinhard Hilgers,Matthias Hansen,Mirja Wedekin,Nicole C. Meyer,Susanne Klaiber,Michaela Gessner,Max C. Liebau,Anne Kristin Vogt-Weigeldt,Therese Jungraithmayr,Sabine Ponsel,Ulrike Jacoby,Martin Konrad,Brigitta Kranz,Jens Koenig,Lisa Loechtermann,M Pohl,Ralf Husain,Katrin Mueller,Julia Thumfart,Gesa Schalk,Markus Feldkoetter,Sabine Schmidt,Katja Sauerstein,Evelin Muschiol,Heiko Billing,Frauke Wilkening +54 more
TL;DR: The study shows the safety of early initiation of therapy and supports the hope to slow renal failure by many years, emphasizing the value of preemptive therapy.